[{"publication_status":"published","issue":"6","publication":"Therapeutic Advances in Neurological Disorders","user_id":"220548","type":"journal_article","publication_identifier":{"issn":["1756-2864"],"eissn":["1756-2864"]},"volume":2,"date_created":"2026-03-02T10:03:31Z","title":"Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy","quality_controlled":"1","language":[{"iso":"eng"}],"_id":"6659","year":"2009","date_updated":"2026-03-17T15:29:33Z","publisher":"SAGE Publications","page":"349-355","doi":"10.1177/1756285609343480","intvolume":"         2","status":"public","citation":{"ieee":"C. Lukas <i>et al.</i>, “Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy,” <i>Therapeutic Advances in Neurological Disorders</i>, vol. 2, no. 6, pp. 349–355, 2009.","alphadin":"<span style=\"font-variant:small-caps;\">Lukas, Carsten</span> ; <span style=\"font-variant:small-caps;\">Bellenberg, Barbara</span> ; <span style=\"font-variant:small-caps;\">Hahn, Horst K.</span> ; <span style=\"font-variant:small-caps;\">Rexilius, Jan</span> ; <span style=\"font-variant:small-caps;\">Drescher, Robert</span> ; <span style=\"font-variant:small-caps;\">Hellwig, Kerstin</span> ; <span style=\"font-variant:small-caps;\">Köster, Odo</span> ; <span style=\"font-variant:small-caps;\">Schimrigk, Sebastian</span>: Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy. In: <i>Therapeutic Advances in Neurological Disorders</i> Bd. 2, SAGE Publications (2009), Nr. 6, S. 349–355","apa":"Lukas, C., Bellenberg, B., Hahn, H. K., Rexilius, J., Drescher, R., Hellwig, K., … Schimrigk, S. (2009). Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy. <i>Therapeutic Advances in Neurological Disorders</i>, <i>2</i>(6), 349–355. <a href=\"https://doi.org/10.1177/1756285609343480\">https://doi.org/10.1177/1756285609343480</a>","bibtex":"@article{Lukas_Bellenberg_Hahn_Rexilius_Drescher_Hellwig_Köster_Schimrigk_2009, title={Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy}, volume={2}, DOI={<a href=\"https://doi.org/10.1177/1756285609343480\">10.1177/1756285609343480</a>}, number={6}, journal={Therapeutic Advances in Neurological Disorders}, publisher={SAGE Publications}, author={Lukas, Carsten and Bellenberg, Barbara and Hahn, Horst K. and Rexilius, Jan and Drescher, Robert and Hellwig, Kerstin and Köster, Odo and Schimrigk, Sebastian}, year={2009}, pages={349–355} }","chicago":"Lukas, Carsten, Barbara Bellenberg, Horst K. Hahn, Jan Rexilius, Robert Drescher, Kerstin Hellwig, Odo Köster, and Sebastian Schimrigk. “Benefit of Repetitive Intrathecal Triamcinolone Acetonide Therapy in Predominantly Spinal Multiple Sclerosis: Prediction by Upper Spinal Cord Atrophy.” <i>Therapeutic Advances in Neurological Disorders</i> 2, no. 6 (2009): 349–55. <a href=\"https://doi.org/10.1177/1756285609343480\">https://doi.org/10.1177/1756285609343480</a>.","short":"C. Lukas, B. Bellenberg, H.K. Hahn, J. Rexilius, R. Drescher, K. Hellwig, O. Köster, S. Schimrigk, Therapeutic Advances in Neurological Disorders 2 (2009) 349–355.","mla":"Lukas, Carsten, et al. “Benefit of Repetitive Intrathecal Triamcinolone Acetonide Therapy in Predominantly Spinal Multiple Sclerosis: Prediction by Upper Spinal Cord Atrophy.” <i>Therapeutic Advances in Neurological Disorders</i>, vol. 2, no. 6, SAGE Publications, 2009, pp. 349–55, doi:<a href=\"https://doi.org/10.1177/1756285609343480\">10.1177/1756285609343480</a>.","ama":"Lukas C, Bellenberg B, Hahn HK, et al. Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper spinal cord atrophy. <i>Therapeutic Advances in Neurological Disorders</i>. 2009;2(6):349-355. doi:<a href=\"https://doi.org/10.1177/1756285609343480\">10.1177/1756285609343480</a>"},"author":[{"first_name":"Carsten","full_name":"Lukas, Carsten","last_name":"Lukas"},{"first_name":"Barbara","full_name":"Bellenberg, Barbara","last_name":"Bellenberg"},{"first_name":"Horst K.","last_name":"Hahn","full_name":"Hahn, Horst K."},{"orcid":"0000-0002-4579-214X","full_name":"Rexilius, Jan","last_name":"Rexilius","first_name":"Jan","orcid_put_code_url":"https://api.orcid.org/v2.0/0000-0002-4579-214X/work/207121134","id":"245736"},{"first_name":"Robert","last_name":"Drescher","full_name":"Drescher, Robert"},{"first_name":"Kerstin","last_name":"Hellwig","full_name":"Hellwig, Kerstin"},{"full_name":"Köster, Odo","last_name":"Köster","first_name":"Odo"},{"first_name":"Sebastian","full_name":"Schimrigk, Sebastian","last_name":"Schimrigk"}]}]